You are here: Home ยป Archives for health

New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome

  • Advanced analytical methods integrating clinical trial and real-world data address key evidence gaps in rare, difficult-to-treat blood cancers 
  • Across both studies, mogamulizumab was associated with improved survival outcomes compared to standard of care

PRINCETON, N.J., June 30, 2026 (GLOBE NEWSWIRE) — Researchers at the World Congress of Cutaneous Lymphoma 2026 presented two indirect treatment comparison (ITC) analyses examining the impact of mogamulizumab on long-term outcomes, including overall survival (OS), in patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL). These findings, which drew on clinical trial and real-world data, expand the growing body of evidence supporting mogamulizumab use and address critical information gaps where comparative survival data have been limited. The research was funded by Kyowa Kirin Co. Ltd (TSE: 4151).

“Indirect treatment comparisons help to bridge critical evidence gaps in MF and SS, giving clinicians a clearer picture of long-term outcomes in real-world practice,” said Professor H. Miles Prince, Principal Investigator, Peter MacCallum Cancer Centre in Melbourne, Australia. “This deeper understanding enables us to make informed treatment decisions and ultimately provide more personalized, effective care for our patients.”

MF and SS are rare, progressive forms of CTCL associated with substantial morbidity in advanced stages and often require multiple lines of treatment. In the phase 3 MAVORIC trial, mogamulizumab improved progression-free survival versus vorinostat in adult patients with relapsed or refractory MF or SS, but a high rate of treatment crossover limited direct assessment of overall survival.

To address this limitation, two independent studies used MAVORIC and real-world data to estimate comparative OS using ITC methods while accounting for patient differences across treatment groups and data sources. These findings aim to help address evidence gaps that limit access in some countries and support informed treatment decision-making.

“In rare diseases like CTCL, clinical trials are often not designed to evaluate long-term treatment outcomes like overall survival,” said Dr. Angela Williams, PhD, Global Head Health Economics and Outcomes Research at Kyowa Kirin. “By applying advanced analytical approaches, we can integrate clinical trial and real-world data to better assess the long-term impact of a treatment like mogamulizumab on overall survival and other outcomes. This approach reflects our continued commitment to advancing research that informs treatment decisions in rare, hard-to-treat hematologic malignancies like CTCL, helping to improve the lives of patients and their care partners.”

ITC Methodology and Results

In two separate ITC studies, researchers analyzed survival outcomes in cohorts of patients with relapsed or refractory MF or SS by comparing patient-level data from the mogamulizumab arm of the MAVORIC trial (n=186) with real-world registry data from Australia and Denmark. Vorinostat, the active comparator in MAVORIC, is part of the standard of care in Australia but unavailable in Denmark. Key limitations of these analyses include the retrospective nature of the studies and potential differences in advances and standards of care over time.

Australia (Campbell BA, et al): Real-world data from the Australian Peter MacCallum Cancer Centre Cutaneous Lymphoma database included 67 patients treated with vorinostat between January 2005 and November 2024. After adjusting for baseline differences:

  • Median OS was not reached for patients receiving mogamulizumab, compared with 31.0 months for patients receiving vorinostat.
  • Mogamulizumab was associated with a significantly lower risk of death compared with vorinostat (hazard ratio [95% confidence interval]: 0.48 [0.30, 0.76]; p=0.002).
  • Median time to next treatment (TTNT) was numerically longer with mogamulizumab versus vorinostat (9.13 months vs. 5.82 months; hazard ratio [95% confidence interval]: 0.76 [0.52, 1.11]; p=0.20), though this difference was not statistically significant.

Denmark (Morgante N, et al): Real-world data from Danish national registries included 209 patients receiving standard of care treatment between January 1996 and April 2024. After statistical weighting: 

  • Patients receiving mogamulizumab did not reach median OS, compared with 17.0 months for patients receiving standard of care.
  • Mogamulizumab was associated with a significantly lower risk of death versus standard of care (hazard ratio [95% confidence interval]: 0.38 [0.25, 0.59]; p<0.001).

U.S. POTELIGEO (mogamulizumab-kpkc) Indication

POTELIGEO injection for intravenous infusion is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

Important Safety Information

WARNINGS AND PRECAUTIONS

Dermatologic toxicity: Monitor patients for rash throughout the course of treatment. For patients who experienced dermatologic toxicity in Trial 1, the median time to onset was 15 weeks, with 25% of cases occurring after 31 weeks. Interrupt POTELIGEO for moderate or severe rash (Grades 2 or 3). Permanently discontinue POTELIGEO for life-threatening (Grade 4) rash or for any Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).

Infusion reactions: Most infusion reactions occur during or shortly after the first infusion. Infusion reactions can also occur with subsequent infusions. Monitor patients closely for signs and symptoms of infusion reactions and interrupt the infusion for any grade reaction and treat promptly. Permanently discontinue POTELIGEO for any life-threatening (Grade 4) infusion reaction.

Infections: Monitor patients for signs and symptoms of infection and treat promptly.

Autoimmune complications: Interrupt or permanently discontinue POTELIGEO as appropriate for suspected immune-mediated adverse reactions. Consider the benefit/risk of POTELIGEO in patients with a history of autoimmune disease.

Complications of allogeneic HSCT after POTELIGEO: Increased risks of transplant complications have been reported in patients who received allogeneic HSCT after POTELIGEO. Follow patients closely for early evidence of transplant-related complications.

ADVERSE REACTIONS

The most common adverse reactions (reported in ≥10% of patients) with POTELIGEO in the clinical trial were rash, including drug eruption (35%), infusion reaction (33%), fatigue (31%), diarrhea (28%), drug eruption (24%), upper respiratory tract infection (22%), musculoskeletal pain (22%), skin infection (19%), pyrexia (17%), edema (16%), nausea (16%), headache (14%), thrombocytopenia (14%), constipation (13%), anemia (12%), mucositis (12%), cough (11%), and hypertension (10%).

You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information in full Prescribing Information as well as Patient Information.

About Kyowa Kirin

Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato-oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe.  You can learn more about the business of Kyowa Kirin at www.kyowakirin.com.

COR-US-POT-0016 June 2026


GLOBENEWSWIRE (Distribution ID 9753760)

New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome

  • Clinically meaningful improvements in skin symptoms reported as early as week 4 and sustained over the 48-week study period 
  • Data presented at the 6th World Congress of Cutaneous Lymphomas meeting in Montreal, Canada

PRINCETON, N.J., June 29, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced positive results from PROSPER, a real-world observational study of mogamulizumab in adults with mycosis fungoides (MF) or Sézary syndrome (SS). In the study, patients reported clinically meaningful improvements in skin symptoms (itch, flaking, and redness) and body temperature regulation as early as week 4, with improvements in sleep and health-related quality of life (HRQoL) starting at week 12. Improvements were sustained throughout the study period, with additional gains in HRQoL reported through week 48.

“Cutaneous T-cell lymphoma can affect far more than just the skin, impacting how patients feel and function every day,” said Professor Julia Scarisbrick, Principal Investigator, Honorary Professor of Dermatology, University Hospitals Birmingham NHS Foundation Trust. “These findings from the PROSPER study are encouraging because they show that in patients with MF or SS, mogamulizumab can help ease symptoms that affect everyday life, and those improvements can be long-lasting.”

Mycosis fungoides and Sézary syndrome are two sub-types of cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma that primarily affects the skin, presenting as patches, plaques, tumors, or reddening of the entire skin, and may be associated with severe itching. The disease may spread to lymph nodes, blood, and/or other organs in some patients.

“Clinical studies are stronger when they are shaped by the voices and lived experiences of people living with the disease,” said Susan Thornton, study author and co-CEO, Cutaneous Lymphoma Foundation. “Collaboration between industry and the patient community is essential to designing studies that generate more relevant insights into symptom burden, quality of life, and the day-to-day treatment experience.”

Key PROSPER Findings

The study included 73 patients with relapsed or refractory MF or SS (n=41 MF; n=32 SS). Patient-reported outcomes were collected at baseline and throughout the study using:

  • A CTCL-specific symptom diary assessing the severity of skin itch, pain, redness, and flaking, frequency of sleep problems, and difficulty regulating body temperature
  • The MF/SS-CTCL-QoL questionnaire, which measured the impact of CTCL on daily life
  • The Brief Fatigue Inventory (BFI), which assessed fatigue severity and its impact on daily functioning

Mean symptom scores (mean +/- standard deviation) improved from baseline to week 48 across key skin symptoms, including itch (−2.5 ±3.4), flaking (−3.1 ±3.5), redness (−3.1 ±3.5), and pain (−1.7 ±4.4). Clinically meaningful improvements in skin itch, flaking, and redness were observed as early as week 4, and improvements in pain by week 12   (i.e., exceeding the minimum important difference (MID)). These effects were sustained through week 48.

By week 48, 30% of patients reported at least a 2-point improvement in sleep, and 37% reported better body temperature regulation. Patients also showed significant, clinically meaningful improvements in disease-specific health-related quality-of-life scores (MF/SS-CTCL-QoL) beginning at week 12, with further gains through week 48. While fatigue scores changed little among patients with MF, patients with SS showed a significant improvement in total BFI scores, reaching the MID threshold at week 48.

“Studies like PROSPER show why real-world data generation matters, particularly in rare cancers like mycosis fungoides and Sézary syndrome,” said Angela Williams, PhD, Global Head of Health Economics and Outcomes Research at Kyowa Kirin. “These data help broaden understanding of the lived experience of patients and care partners with mogamulizumab treatment in everyday practice, including the impact on symptoms and quality-of-life that may not be fully reflected by outcomes collected in clinical trial.”

About PROSPER

The objective of the PROSPER (ClinicalTrials.gov ID NCT05455931) study is to gain insight into the experiences of patients with MF or SS receiving mogamulizumab in real-world clinical practice through the collection of patient-reported outcomes (PRO) data, enriched with qualitative data on disease and treatment experience. The study was designed with input from patients and caregivers to ensure patient-relevant outcomes were selected, and it was conducted in six countries across North America, Europe, and the Middle East, at 19 sites working with patients with MF or SS. Patients were followed for up to 50 weeks from study enrollment.

U.S. POTELIGEO (mogamulizumab-kpkc) Indication

POTELIGEO injection for intravenous infusion is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

Important Safety Information

WARNINGS AND PRECAUTIONS

Dermatologic toxicity: Monitor patients for rash throughout the course of treatment. For patients who experienced dermatologic toxicity in Trial 1, the median time to onset was 15 weeks, with 25% of cases occurring after 31 weeks. Interrupt POTELIGEO for moderate or severe rash (Grades 2 or 3). Permanently discontinue POTELIGEO for life-threatening (Grade 4) rash or for any Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).

Infusion reactions: Most infusion reactions occur during or shortly after the first infusion. Infusion reactions can also occur with subsequent infusions. Monitor patients closely for signs and symptoms of infusion reactions and interrupt the infusion for any grade reaction and treat promptly. Permanently discontinue POTELIGEO for any life-threatening (Grade 4) infusion reaction.

Infections: Monitor patients for signs and symptoms of infection and treat promptly.

Autoimmune complications: Interrupt or permanently discontinue POTELIGEO as appropriate for suspected immune-mediated adverse reactions. Consider the benefit/risk of POTELIGEO in patients with a history of autoimmune disease.

Complications of allogeneic HSCT after POTELIGEO: Increased risks of transplant complications have been reported in patients who received allogeneic HSCT after POTELIGEO. Follow patients closely for early evidence of transplant-related complications.

ADVERSE REACTIONS

The most common adverse reactions (reported in ≥10% of patients) with POTELIGEO in the clinical trial were rash, including drug eruption (35%), infusion reaction (33%), fatigue (31%), diarrhea (28%), drug eruption (24%), upper respiratory tract infection (22%), musculoskeletal pain (22%), skin infection (19%), pyrexia (17%), edema (16%), nausea (16%), headache (14%), thrombocytopenia (14%), constipation (13%), anemia (12%), mucositis (12%), cough (11%), and hypertension (10%).

You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information in full Prescribing Information as well as Patient Information.

About Kyowa Kirin

Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato-oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe.  You can learn more about the business of Kyowa Kirin at www.kyowakirin.com.

COR-US-POT-0015 June 2026


GLOBENEWSWIRE (Distribution ID 9753764)

Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL

PRINCETON, N.J., June 10, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new data further defining the potential of mogamulizumab in the treatment of relapsed or refractory mycosis fungoides and Sézary syndrome, two subtypes of cutaneous T-cell lymphoma, will be featured at the World Congress of Cutaneous Lymphomas (WCCL) in Montréal, Canada.

Drawing on complementary evidence streams, including patient-reported outcomes, comparative-effectiveness estimates, molecular biomarker signals, and real-world utilization, these analyses collectively provide a more complete understanding of the therapeutic profile and potential of mogamulizumab.

“The research being presented at WCCL reflects our continued commitment to generating evidence beyond initial clinical trials for mogamulizumab in patients with relapsed or refractory mycosis fungoides and Sézary syndrome,” said Daniela van Eickels, MD, PhD, MPH, Chief Medical Officer, Kyowa Kirin North America. “In these difficult-to-treat blood cancers, innovative clinical research and real-world data generation is essential to advancing and informing treatment strategies. We look forward to sharing our findings and exchanging ideas with the expert community.”  

WCCL Presentations: 

Improved symptoms and health-related quality of life in patients with mycosis fungoides and Sézary syndrome treated with mogamulizumab in the PROSPER study
Oral Presentation; Scientific Session 8A
Friday, June 26, 3:30-4:30 PM ET

Outcomes in relapsed/refractory mycosis fungoides or Sézary syndrome from the MAVORIC trial mogamulizumab arm versus a real-world Australian cohort receiving vorinostat
(Collaborative Study)
Oral Presentation; Scientific Session 3B
Thursday, June 25, 2:30-3:30 PM ET

Overall survival in patients with mycosis fungoides or Sézary syndrome in Denmark: comparative effectiveness of mogamulizumab versus standard of care
Oral Presentation; Scientific Session 3B
Thursday, June 25, 2:30-3:30 PM ET

Targeted sequencing in patients with relapsed/refractory mycosis fungoides mogamulizumab or Sézary syndrome treated with mogamulizumab in the MOGA-2MG-Q4W clinical trial  
Oral Presentation; Scientific Session 4B
Thursday, June 25, 3:40-5:20 PM ET

Mogamulizumab treatment for mycosis fungoides in clinical practice in France: data from the ongoing multicentric prospective observational PROMED study
Exhibit Hall Poster Session
Thursday-Saturday, June 25-27

U.S. POTELIGEO (mogamulizumab-kpkc) Indication 
POTELIGEO injection for intravenous infusion is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. 

Important Safety Information 

WARNINGS AND PRECAUTIONS 

Dermatologic toxicity: Monitor patients for rash throughout the course of treatment. For patients who experienced dermatologic toxicity in Trial 1, the median time to onset was 15 weeks, with 25% of cases occurring after 31 weeks. Interrupt POTELIGEO for moderate or severe rash (Grades 2 or 3). Permanently discontinue POTELIGEO for life-threatening (Grade 4) rash or for any Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). 

Infusion reactions: Most infusion reactions occur during or shortly after the first infusion. Infusion reactions can also occur with subsequent infusions. Monitor patients closely for signs and symptoms of infusion reactions and interrupt the infusion for any grade reaction and treat promptly. Permanently discontinue POTELIGEO for any life-threatening (Grade 4) infusion reaction. 

Infections: Monitor patients for signs and symptoms of infection and treat promptly. 

Autoimmune complications: Interrupt or permanently discontinue POTELIGEO as appropriate for suspected immune-mediated adverse reactions. Consider the benefit/risk of POTELIGEO in patients with a history of autoimmune disease. 

Complications of allogeneic HSCT after POTELIGEO: Increased risks of transplant complications have been reported in patients who received allogeneic HSCT after POTELIGEO. Follow patients closely for early evidence of transplant-related complications. 

ADVERSE REACTIONS 

The most common adverse reactions (reported in ≥10% of patients) with POTELIGEO in the clinical trial were rash, including drug eruption (35%), infusion reaction (33%), fatigue (31%), diarrhea (28%), drug eruption (24%), upper respiratory tract infection (22%), musculoskeletal pain (22%), skin infection (19%), pyrexia (17%), edema (16%), nausea (16%), headache (14%), thrombocytopenia (14%), constipation (13%), anemia (12%), mucositis (12%), cough (11%), and hypertension (10%). 

You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 

Please see additional Important Safety Information in full Prescribing Information as well as Patient Information. 

About Kyowa Kirin 
Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato-oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe. You can learn more about the business of Kyowa Kirin at www.kyowakirin.com.  


GLOBENEWSWIRE (Distribution ID 9734113)

World Vape Day 2026: One Switch – Everyone Wins

BRUSSELS, May 30, 2026 (GLOBE NEWSWIRE) — Today, vapers, former smokers, and harm reduction advocates mark World Vape Day 2026. The theme this year is One Switch – Everyone Wins. It is not a slogan. It is what the data shows.

World Vape Day falls one day before the WHO's World No Tobacco Day, and the contrast could not be starker. While the WHO spends tomorrow calling vapes and nicotine pouches industry tricks designed to hook a new generation, consumers in Germany, South Africa, Argentina, and many more countries took to the streets and Social Media this week to demand access to the less harmful alternatives that have already helped millions quit smoking.

“The WHO has been running the same playbook for years. Nicotine is the enemy, alternatives are industry tactics, and anyone who disagrees is compromised. Meanwhile, 8 million people a year die from smoking. That is not a public health record to be proud of,” said Michael Landl, Director, World Vapers' Alliance.

The science is not in dispute among serious researchers. Vaping, nicotine pouches, and heated tobacco products all dramatically reduce exposure to the chemicals that kill smokers. Nicotine is addictive, but it is not the cause of smoking-related disease. Combustion is. When a smoker switches completely, the benefits extend to everyone around them. Secondhand smoke raises children's risk of asthma, pneumonia, and bronchitis. Children of smokers are up to four times more likely to become smokers themselves. One switch removes almost all of that from the home.

The countries that understood this are now reaping the results. Sweden is smoke-free. The UK halved its smoking rate. New Zealand cut smoking among under-25s to around 3 percent and has the first smoke-free generation.

“Every country that has cut smoking fast did it by giving smokers real alternatives. World Vape Day exists to remind policymakers that the evidence is there. That we consumers are not anecdotes, we are the evidence. The tools are there. The only thing missing is the political will in too many countries,” Landl added.

For media enquiries: [email protected] www.worldvapersalliance.com

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/01526a12-daff-4be4-aa21-2454f91a5e71


GLOBENEWSWIRE (Distribution ID 9729184)

Dia Mundial do Vape 2026: Uma Mudança, Todos Ganham

BRUXELAS, May 30, 2026 (GLOBE NEWSWIRE) — Hoje, vapers, ex-fumantes e defensores da redução de danos marcam o Dia Mundial do Vape 2026. O tema deste ano é Uma Mudança, Todos Ganham. Não é um slogan. É o que os dados mostram.

O Dia Mundial do Vape acontece um dia antes do Dia Mundial Sem Tabaco da OMS, e o contraste não poderia ser mais gritante. Enquanto a OMS passa o amanhã chamando vapes e truques da indústria de bolsas de nicotina projetadas para atrair uma nova geração, consumidores na Alemanha, África do Sul, Argentina e muitos outros países foram às ruas e às redes sociais esta semana para exigir acesso às alternativas menos prejudiciais que já ajudaram milhões a parar de fumar.

“A OMS usa a mesma cartilha há anos. A nicotina é o inimigo, as alternativas são táticas da indústria e qualquer um que discorde está comprometido. Enquanto isso 8 milhões de pessoas morrem por ano por causa do tabagismo. Esse não é um registro de saúde pública para se orgulhar “, disse Michael Landl, Diretor da World Vapers 'Alliance.

A ciência não está em disputa entre pesquisadores sérios. Vaping, bolsas de nicotina e produtos de tabaco aquecido reduzem drasticamente a exposição aos produtos químicos que matam os fumantes. A nicotina é viciante, mas não é a causa das doenças relacionadas ao tabagismo. A fumaça é. Quando um fumante muda completamente, os benefícios se estendem a todos ao seu redor. O fumo passivo aumenta o risco de asma, pneumonia e bronquite nas crianças. Os filhos de fumantes são até quatro vezes mais propensos a se tornarem fumantes. Uma mudança acaba quase com tudo isso na casa.

Os países que entenderam isso agora estão colhendo os resultados. A Suécia está livre do tabagismo. O Reino Unido reduziu pela metade sua taxa de tabagismo. A Nova Zelândia reduziu o tabagismo entre os menores de 25 anos para cerca de 3% e tem a primeira geração livre do tabagismo.

“Todos os países que reduziram o tabagismo rapidamente fizeram isso dando aos fumantes alternativas reais. O Dia Mundial do Vape existe para lembrar aos formuladores de políticas da existência de evidências. Nós, consumidores, não somos apenas casos, somos a evidência. As ferramentas existem. A única coisa que falta é a vontade política em muitos países “, acrescentou Landl.

Para perguntas da mídia: [email protected] www.worldvapersalliance.com

Foto deste comunicado disponível em: https://www.globenewswire.com/NewsRoom/AttachmentNg/01526a12-daff-4be4-aa21-2454f91a5e71


GLOBENEWSWIRE (Distribution ID 9729184)

Hanmi Pharmaceutical تتعاون مع Organon لتصدير علاجات مركبة إلى جنوب شرق آسيا

Shin Hae-gon (إلى اليمين)، مدير المبيعات الدولية في شركة Hanmi Pharmaceutical، وAndreas Daugaard Jørgensen (إلى اليسار)، المدير الإداري لمجموعة Organon في آسيا والمحيط الهادئ، التقيا في مكتب Organon في ماليزيا لبحث توسيع انتشار العلاجات المركبة التي تنتجها Hanmi في أسواق منطقة جنوب شرق آسيا.

سيول، كوريا الجنوبية،, May 21, 2026 (GLOBE NEWSWIRE) —  أعلنت شركة Hanmi Pharmaceutical عن توقيع اتفاقية توريد مع شركة الرعاية الصحية العالمية Organon لتصدير ثلاثة أدوية مركّبة إلى أسواق ماليزيا والفلبين، في إطار الجهود الرامية إلى توسيع من نطاق الشراكة بين الشركتين في منطقة جنوب شرق آسيا.

وبموجب الاتفاقية، ستقوم Hanmi بتوريد ثلاثة أدوية مركّبة جاهزة مخصّصة لعلاج أمراض القلب والجهاز التنفسي، على أن تتولى Organon مسؤولية عمليات التسويق والتوزيع والمبيعات في الأسواق المحلية. كما تخطط الشركتان للمضي قدماً في الحصول على الموافقات التنظيمية وإطلاق المنتجات بشكل تدريجي في ماليزيا والفلبين، مع إمكانية توسيع نطاق تعاونهما على المدى المتوسط والطويل.

هذا وتُعد Organon، التي تأسست عام 2021، شركة عالمية متخصصة في الرعاية الصحية، وتمتلك محفظة تضم أكثر من 70 منتجاً تغطي مجموعة واسعة من المجالات العلاجية. وبفضل قدراتها التجارية المتقدمة وشبكة التصنيع الموثوقة التي تملكها، تتيح الشركة وصول هذه الأدوية والأجهزة الطبية الحيوية إلى المرضى في أكثر من 140 سوقاً حول العالم، بما في ذلك أسواق جنوب شرق آسيا.

وقد سبق لشركة Hanmi Pharmaceutical أن عززت حضورها العالمي من خلال إبرام شراكات مع شركات دوائية متعددة الجنسيات. ويستند الاتفاق الحالي مع Organon إلى خبرةHanmi في التعاونات الدولية، ومن المتوقع أن يدعم خطط الشركة للتوسع التجاري في أسواق جنوب شرق آسيا.

تُعد منطقة جنوب شرق آسيا واحدة من أسرع أسواق الأدوية نمواً في العالم، مدفوعة بزيادة عدد السكان وارتفاع وتيرة انتشار الأمراض المزمنة. وعلى وجه الخصوص، يشهد الطلب على العلاجات المركبة ارتفاعاً ملحوظاً، مع تزايد أعداد المرضى المصابين بحالات مرضية مزمنة مثل ارتفاع ضغط الدم.

وفي هذا السياق، قال Mazen Altaruti، رئيس قسم الأسواق الناشئة في شركة Organon: “تلتزم Organon بتوفير الأدوية التي تلبي أبرز الاحتياجات الصحية في المجتمعات التي نخدمها. إن هذه الشراكة معHanmi تعكس تركيزنا المشترك على توسيع نطاق وصول المرضى إلى الخيارات العلاجية في ماليزيا والفلبين، وتعزيز فرص الوصول العادل إلى الرعاية الصحية في مختلف أنحاء المنطقة“.

من جانبه، قال Sean Hwang، الرئيس التنفيذي لشركة Hanmi Pharmaceutical: “ستواصلHanmi تسريع وتيرة توسّعها العالمي من خلال محفظتها المتنوعة من العلاجات المركّبة، التي تُعد إحدى نقاط القوة الأساسية للشركة. ومن خلال تعاوننا مع Organon، نهدف إلى تحسين الوصول إلى العلاج لخدمة المرضى في منطقة جنوب شرق آسيا”.

  • جهات الاتصال:

المواقع الرسمية : www.hanmipharm.com، www.linkedin.com/company/hanmipharm،  [email protected]، +82024100467

الصورة المرفقة بهذا البيان الصحفي متاحة عبر الرابط الالكتروني التالي: https://www.globenewswire.com/NewsRoom/AttachmentNg/b62e29c9-0e09-4dad-9cb8-6e47fb8415db


GLOBENEWSWIRE (Distribution ID 9724703)

Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia

Shin Hae-gon (right), Head of Overseas Sales at Hanmi Pharmaceutical, and Andreas Daugaard Jørgensen (left), Managing Director, Organon Asia Pacific Cluster, met at Organon’s Malaysia office to discuss the expansion of Hanmi’s combination therapies into the Southeast Asian market.

SEOUL, South Korea, May 21, 2026 (GLOBE NEWSWIRE) — Hanmi Pharmaceutical announced that it has signed a supply agreement with global healthcare company Organon to export three combination medicines for the Malaysian and Philippine markets, expanding the companies’ partnership in Southeast Asia.

Under the agreement, Hanmi will supply three finished combination products in the cardiovascular and respiratory therapeutic areas, while Organon will be responsible for marketing, distribution, and sales in the local markets. The two companies plan to pursue phased regulatory approvals and product launches in Malaysia and the Philippines, with the potential to expand their collaboration over the mid to long term.

Organon, established in 2021 is a global healthcare company with a portfolio of over 70 products across a range of therapeutic areas. Through a deep commercial ability and trusted manufacturing network, Organon brings these important medicines and devices to patients when and where they need them in over 140 markets, including Southeast Asia.

Hanmi Pharmaceutical has previously expanded its global presence through partnerships with multinational pharmaceutical companies. The current agreement with Organon builds on Hanmi’s experience in global collaborations and is expected to support the company’s commercial expansion in the Southeast Asian market.

Southeast Asia is widely regarded as a rapidly growing pharmaceutical market driven by population growth and the increasing prevalence of chronic diseases. In particular, demand for combination therapies is rising as the number of patients with chronic conditions such as hypertension continues to increase.

“At Organon, we are committed to improving access to medicines that address the greatest health needs in the communities we serve,” said Mazen Altaruti, President, Organon Emerging Markets. “This partnership with Hanmi reflects our shared focus on expanding treatment options for patients in Malaysia and the Philippines and advancing more equitable access to care across the region.”

Sean Hwang, CEO of Hanmi Pharmaceutical, said, “Hanmi will continue accelerating its global expansion with our diverse portfolio of combination therapies, which represent one of the company’s core strengths. Through our collaboration with Organon, we aim to improve treatment accessibility for patients in Southeast Asia.”

■ Contact info:

Official Websites: www.hanmipharm.com, www.linkedin.com/company/hanmipharm
[email protected], +82-02-410-0467

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b62e29c9-0e09-4dad-9cb8-6e47fb8415db


GLOBENEWSWIRE (Distribution ID 9724569)

Countdown Grant Explores How Cells Remove Damaged Mitochondria — Opening New Possibilities Across Parkinson’s, Chronic Disease, Rare Disease, and Aging

ATLANTA, May 15, 2026 (GLOBE NEWSWIRE) — Countdown, a nonprofit accelerating mitochondrial science and medicine across the full spectrum of human health, announced a new research grant awarded to Dr. Elias Adriaenssens at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria. 

The funding will support a groundbreaking project titled From Hypoxia to Therapy: Unlocking Mitochondrial Clearance Pathways for Disease Treatment, focused on understanding how cells identify, clear, and renew damaged mitochondria, the tiny structures responsible for producing the energy every cell in the body needs to survive and function. 

Mitochondrial dysfunction is a foundational and shared driver across many of today’s most pressing health challenges, from rare and chronic disease to neurodegeneration, metabolic disease, and age-related decline. Yet despite mitochondria’s central role in human health, many of the underlying cellular quality-control mechanisms remain poorly understood. 

One of the most promising emerging areas in mitochondrial medicine is hypoxia therapy, the controlled reduction of oxygen exposure to activate protective cellular pathways. Hypoxia has emerged as a potential therapeutic strategy across a broad range of conditions and diseases, including primary mitochondrial diseases, Parkinson’s, ischemic injury, and age-related decline. Yet despite its therapeutic promise, chronic systemic hypoxia is difficult to implement clinically, requiring prolonged exposure to tightly controlled low-oxygen environments that are not realistically compatible with everyday life. Moreover, systemic hypoxia can induce widespread stress responses and undesirable biological adaptations across multiple tissues.

Dr. Adriaenssens’ research seeks to solve one of the field’s most important challenges: how to isolate the beneficial mitochondrial effects of hypoxia without exposing patients to its dangerous systemic consequences. Every cell has a built-in system for removing damaged mitochondria and maintaining cellular health. When that process breaks down, damaged mitochondria can accumulate inside cells, triggering inflammation, dysfunction, and tissue damage throughout the body. 

The project focuses on a poorly understood mitochondrial quality-control pathway, which appears to act as a brake on the cell’s mitochondrial renewal system. The research aims to identify how to selectively activate protective mitochondrial clearance pathways associated with hypoxia, without triggering the dangerous systemic effects of whole-body hypoxia. 

The long-term goal is to help lay the foundation for therapies that could mimic the protective effects of hypoxia through patient-compatible treatments, eliminating  the impractical and potentially dangerous need for continuous low-oxygen exposure or hypoxic chambers. 

What makes this research especially significant is that cells contain multiple pathways for removing damaged mitochondria, yet science has only deeply understood one of them. By uncovering alternative mitochondrial clearance mechanisms, this research could open new therapeutic possibilities across a wide range of diseases and conditions where mitochondrial dysfunction plays a central role.

The findings may also help advance one of medicine’s most promising emerging frontiers: mitochondrial transplantation. While early studies suggest transplanted mitochondria could help rescue damaged tissues, one of the biggest barriers remains that healthy mitochondria are often recognized and destroyed by the cell before they can successfully integrate and function. Understanding these newly identified quality-control pathways may help overcome that challenge and make mitochondrial transplantation more durable and effective. 

“Countdown funds research at a cellular level, the shared biology beneath conditions that most organizations address in isolation,” said Mitzi Solomon, Founder and President of Countdown. “This grant exemplifies the broad-reaching implications of mitochondrial research, as the molecular insight Dr. Adriaenssens is pursuing could ultimately benefit patients across rare disease, neurodegeneration, heart disease, transplantation, and aging — all at once.” 

“For patients with mitochondrial dysfunction, the options today are still largely supportive. This research moves us toward something genuinely different, a way to selectively activate the cell’s own renewal machinery without the side effects of systemic approaches,” said Dr. Elias Adriaenssens, Research Institute of Molecular Pathology (IMP), Vienna. “Countdown’s investment gives us the runway to do the work that makes rational drug design possible.” 

The grant is made in honor of Countdown board member Gerry King, whose commitment to advancing mitochondrial research while living with Parkinson’s disease reflects the urgency and importance of this work. 

“We are all overwhelmed by the endless requests for support across countless causes and organizations,” said Gerry King, Countdown Board Member. “I made the decision to place my commitment behind Countdown because of its uncompromising passion to uncover the root causes beneath diseases affecting all walks of life. Mitochondrial dysfunction impacts all of us, and I believe mitochondrial research has the potential to change not only the lives of people living with Parkinson’s disease, but the future of human health itself. My support of Countdown and this mission will continue until meaningful breakthroughs — and ultimately cures — are found.” 

 Founded on the belief that mitochondrial health is not a niche concern but a window into nearly every major disease challenge of our time, Countdown funds research across six interconnected pillars — Early Detection & Precision Diagnostics, Women’s Health & Hormonal Longevity, Primary Mitochondrial & Rare Genetic Disease, Chronic Disease & Aging, Brain Energy & Cognitive Resilience, and Advanced Therapeutics & Frontier Innovation. The organization unites scientists, clinicians, philanthropists, and industry partners to move the field forward faster, accelerating discoveries that shape a future where mitochondrial science is central to how we understand, treat, and prevent disease.

About Countdown 

Countdown is a nonprofit focused on accelerating mitochondrial science and medicine across the full spectrum of human health to improve how people feel, function, and age. By focusing on mitochondria — the shared biological network underlying many of the most pressing diseases of our time — Countdown is driving a more integrated approach to accelerating scientific breakthroughs that transform how we understand, prevent, and treat disease at its source. We fund research, expand awareness, and unite scientists, clinicians, philanthropists, industry leaders, and visionary brands to drive real-world impact. Join the Countdown to change the future of health. 

For more information, visit www.joincountdown.org 

About Elias Adriaenssens
Elias Adriaenssens is a postdoctoral researcher in the laboratory of Tim Clausen at the Research Institute of Molecular Pathology (IMP) at the Vienna BioCenter. He joined the Vienna BioCenter in 2019 as a postdoctoral researcher at the neighbouring Max Perutz Labs.

Adriaenssens completed his PhD in molecular biology at the University of Antwerp in Belgium. He also holds a Master’s degree in pharmacology from the University of Oxford (2014), as well as undergraduate and Master’s degrees in biochemistry from the University of Antwerp.

He has received several awards and honours, including a Medical Research Council (MRC) Studentship Award (2013) / Wolfson College High Profile Achievement Award (2014); a Rotary Hope-in-Head Grant (2019); and a Marie Skłodowska-Curie Actions (MSCA) Postdoctoral Fellowship.

About the IMP
The Research Institute of Molecular Pathology (IMP) in Vienna is a basic life science research institute largely sponsored by Boehringer Ingelheim. With over 220 scientists from 40 countries, the IMP is committed to scientific discovery of fundamental molecular and cellular mechanisms underlying complex biological phenomena. The IMP is part of the Vienna BioCenter, one of Europe’s most dynamic life science hubs with 2,800 staff members from over 80 countries in seven research institutions, two universities, and 42 biotech companies. www.imp.ac.at, www.viennabiocenter.org  

Follow Countdown on Instagram, Facebook, LinkedIn, X and YouTube

Contact:
Mitzi Solomon, Founder and President
[email protected] | +1 (917) 715-2381


GLOBENEWSWIRE (Distribution ID 9721487)

neurocare group AG announces MDMA approval of TMS Devices in Saudi Arabia

Munich, Germany and Riyadh, Saudi Arabia – neurocare group AG (“neurocare” or the “Company”), a best practice platform for mental health and performance, is pleased to announce the Saudi Food & Drug Authority (SFDA) has granted the Company Medical Device Marketing Authorization (MDMA) approval to sell its TMS Devices in the Kingdom of Saudi Arabia.

A core part of neurocare’s best practice platform is TMS technology which offers a safe, non-invasive, and drug-free alternative for mental health indications such as depression, yet with no black box warning and no medication-related side effects. As part of the neurocare platform, TMS is embedded into structured clinical workflows and supported by digital tools and measurement-based care, enabling clinicians to deliver more consistent, personalized and sustainable outcomes.

Clinical studies show that approximately 60% of patients achieve remission with TMS, making it a promising new treatment option for adolescents who have not found success with other treatments for depression. 

This milestone marks a significant step forward in neurocare’s efforts to expand access to its advanced best practice platform across the Middle East. With this approval, neurocare becomes one of the first TMS manufacturers authorized to operate in Saudi Arabia, positioning the Company at the forefront of a rapidly developing mental healthcare landscape.

Saudi Arabia is investing heavily in evidence-based, technology-enabled care through its Health Sector Transformation Program, creating strong momentum for the adoption of innovative treatments such as TMS. Across the wider Gulf region, neurocare has seen growing interest specifically in its integrated platform approach, uniting neuromodulation, digital processes and standardized protocols, which is well aligned with the needs of clinicians and health systems seeking reliable alternatives.

With MDMA approval now secured, neurocare is uniquely positioned to bring its proven, state-of-the-art platform led by TMS technology to providers in the Kingdom. This enables clinics to expand their service offerings, improve treatment outcomes, and deliver personalized, nonpharmacological care to patients who need it most.

“We see tremendous potential across the region for adopting innovative, evidence-based methods such as TMS,” said Tariq El-Titi, Senior Vice President for neurocare in MENA. “Healthcare leaders in Saudi Arabia are increasingly looking for advanced, nonpharmacological solutions to support patients. We look forward to forming new partnerships across the Kingdom and supporting clinicians as they integrate best-practice TMS therapies powered by German-engineered technology.”

“This approval reflects our broader mission to empower clinicians through our best practice platform with our TMS technology first,” said Thomas Mechtersheimer, Founder and CEO of neurocare group AG. “By combining advanced neuromodulation, digital tools, and integrated processes, we enable providers to deliver more personalized care and achieve better outcomes for patients across the region.”

“With SFDA approval in place, the priority now is execution—embedding TMS within clinical pathways and expanding access beyond traditional hospital settings,“ added Dr. Helmut Schuehsler, CEO and Chairman of TVM Capital Healthcare. “We look forward to continuing to work closely with partners and regulators to adapt and scale proven platforms such as neurocare’s to the Kingdom’s needs and support growing mental health demand.”

neurocare has been active in the MENA region since 2024 through strategic partnerships that support the expansion of best-practice mental healthcare, complementing the company’s established clinical footprint across Europe, the US, the UK, the Netherlands and Australia. Following TVM Capital Healthcare’s investment, the Company has accelerated its regional expansion, working closely with local partners and regulators to establish and scale its integrated platform that provides neuromodulation and neurofeedback technologies and clinical care in Saudi Arabia. In parallel, neurocare continues to advance access to evidence-based neuromodulation by supporting global efforts to secure reimbursement pathways for TMS and related technologies.

At a time when regional dynamics underscore the importance of resilient healthcare systems that are inclusive of mental well-being, neurocare’s platform can support patients and providers during periods of heightened need with reliable, locally accessible, and personalised care solutions.

About neurocare group AG

neurocare group AG has developed a best practice mental health platform, empowering clinicians to offer their patients, through personalized therapy, the best care for a variety of psychological or neurological conditions with more sustainable clinical outcomes. These therapy plans integrate innovative methods and tools, such as psychotherapy, neuromodulation, and sleep hygiene, as well as medication. Following a detailed assessment of the patient's condition, neurocare supports clinicians in developing personalized therapy plans that improve self-regulation, resilience and social skills, while being cost-effective for the healthcare system.

The key technology elements of neurocare’s platform are developed in-house, including leading TMS and EEG devices, a cloud-based software platform, as well as an online academy to give professionals the tools and neuroscientific understanding to properly apply these approaches in clinical practice.

neurocare’s platform is currently applied throughout the company’s own clinics across the US, the UK, the Netherlands and Australia, as well as in a growing number of third-party clinics.

neurocaregroup.com

Contact:

Sally Remington
neurocare group AG
[email protected]

About TVM Capital Healthcare

TVM Capital Healthcare is a global private equity investor and operator focused on specialty care and healthcare growth capital across emerging markets. With nearly 40 years of global investment and operational experience and 15 years in emerging markets, the firm builds and scales companies in Southeast Asia and the Middle East while also investing in healthcare innovators from the US and Europe and guiding their expansion into these markets. TVM Capital Healthcare’s portfolio companies advance access to care, improve patient outcomes, and align with national healthcare transformation agendas.

tvmcapitalhealthcare.com

Contact:

Holly Radel
TVM Capital Healthcare
[email protected]

Attachment


GLOBENEWSWIRE (Distribution ID 1001179814)

تعلن مجموعة neurocare AG عن ترخيص تسويق الأجهزة الطبية (MDMA) لبيع أجهزة التحفيز المغناطيسي عبر الجمجمة (TMS) في المملكة العربية السعودية

ميونخ، ألمانيا والرياض، المملكة العربية السعودية: تعلن بكل سرور شركة neurocare Group AG (المنوه عنها فيمل يلي بـــ «neurocare» أو «الشركة»)، وهي منصة رائدة تعتمد أفضل الممارسات في مجال الصحة النفسية وتعزيز الأداء، أن الهيئة العامة للغذاء والدواء (SFDA) قد منحت الشركة ترخيص تسويق الأجهزة الطبية (MDMA) لبيع أجهزة التحفيز المغناطيسي عبر الجمجمة (TMS) الخاصة بها في المملكة العربية السعودية.

تُعدّ تكنولوجيا التحفيز المغناطيسي عبر الجمجمة (TMS) جزءًا أساسيًا من منصة «neurocare» القائمة على أفضل الممارسات، حيث توفّر بديلاً آمنًا وغير تدخلي وخاليًا من الأدوية لعلاج اضطرابات الصحة النفسية مثل الاكتئاب، دون تحذيرات من الصندوق الأسود ودون آثار جانبية مرتبطة بالأدوية. وكجزء من منصة «neurocare»، يتم دمج تقنية التحفيز المغناطيسي عبر الجمجمة (TMS) ضمن مسارات علاجية سريرية منظمة، ومدعومة بأدوات رقمية ونهج رعاية قائم على القياس، مما يمكّن الأطباء من تقديم نتائج أكثر اتساقًا وتخصيصًا واستدامة.
وتشير الدراسات السريرية إلى أن نحو 60% من المرضى يحققون حالة من التعافي باستخدام تقنية التحفيز المغناطيسي عبر الجمجمة (TMS) ، مما يجعلها خيارًا علاجيًا جديداً وواعدًا للمراهقين الذين لم يحققوا نتائج ناجحة مع العلاجات الأخرى للاكتئاب.

تمثّل هذه المحطة خطوة مهمة في جهود «neurocare» لتوسيع نطاق الوصول إلى منصتها المتقدمة القائمة على أفضل الممارسات في مختلف أنحاء الشرق الأوسط. ومع هذا الترخيص، تصبح «neurocare» من أوائل الشركات المصنعة لأجهزة التحفيز المغناطيسي عبر الجمجمة (TMS) المرخّص لها بالعمل في المملكة العربية السعودية، مما يضع الشركة في موقع ريادي ضمن مشهد سريع التطور لقطاع الرعاية الصحية النفسية.

تستثمر المملكة العربية السعودية بشكل مكثّف في نماذج الرعاية القائمة على الأدلة والمدعومة بالتكنولوجيا من خلال برنامج تحوّل القطاع الصحي، مما يخلق زخمًا قويًا لاعتماد العلاجات المبتكرة مثل التحفيز المغناطيسي عبر الجمجمة (TMS) وعلى مستوى منطقة الخليج الأوسع، تشهد «neurocare» اهتمامًا متزايدًا بنهجها القائم على المنصة المتكاملة، والذي يجمع بين تعديل النشاط العصبي، والعمليات الرقمية، والبروتوكولات المعيارية التي تتماشى بشكل وثيق مع احتياجات الأطباء وأنظمة الرعاية الصحية الساعية إلى بدائل موثوقة.

ومع الحصول على ترخيص تسويق الأجهزة الطبية (MDMA)، أصبحت «neurocare» في موقع متميز لتقديم منصتها المتطورة والمثبتة، والمدعومة بتقنية التحفيز المغناطيسي عبر الجمجمة (TMS)، إلى مقدمي الرعاية الصحية في المملكة. فيتيح ذلك للعيادات توسيع نطاق خدماتها، وتحسين نتائج العلاج، وتقديم رعاية مخصصة غير دوائية للمرضى الأكثر حاجة إليها.

وأفاد طارق التيتي، النائب الأول للرئيس لشركة «neurocare» في منطقة الشرق الأوسط وشمال أفريقيا: «نرى إمكانات كبيرة في مختلف أنحاء المنطقة لاعتماد أساليب مبتكرة قائمة على الأدلة، مثل التحفيز المغناطيسي عبر الجمجمة (TMS) ويبحث قادة قطاع الرعاية الصحية في المملكة العربية السعودية بشكل متزايد عن حلول متقدمة غير دوائية لدعم المرضى. ونتطلع إلى إقامة شراكات جديدة في مختلف أنحاء المملكة، ودعم الأطباء أثناء دمج علاجات التحفيز المغناطيسي عبر الجمجمة (TMS) القائمة على أفضل الممارسات، والمدعومة بتكنولوجيا مصممة وفق أعلى المعايير الهندسية الألمانية.»

 كما صرّح Thomas Mechtersheimer (توماس مخترشايمر)، المؤسس والرئيس التنفيذي لــــ «مجموعة  neurocare AG»: «يعكس هذا الترخيص مهمتنا الأوسع في تمكين الأطباء من خلال منصتنا القائمة على أفضل الممارسات، مع تركيز أساسي على تقنية التحفيز المغناطيسي عبر الجمجمة (TMS) . ومن خلال الجمع بين تقنيات التعديل العصبي المتقدمة، والأدوات الرقمية، والعمليات المتكاملة، نُمكّن مقدمي الرعاية الصحية من تقديم رعاية أكثر تخصيصًا وتحقيق نتائج أفضل للمرضى في مختلف أنحاء المنطقة.»

وأضاف الدكتور Helmut Schuehsler (هيلموت شوسلر)، الرئيس التنفيذي ورئيس مجلس إدارة شركة
 «TVM Capital Healthcare»: »مع الحصول على موافقة الهيئة العامة للغذاء والدواء (SFDA)، أصبحت الأولوية الآن للتنفيذ – من خلال دمج تقنية التحفيز المغناطيسي عبر الجمجمة (TMS) ضمن المسارات العلاجية السريرية، وتوسيع نطاق الوصول إليها خارج الإعدادات التقليدية للمستشفيات. ونتطلع إلى مواصلة العمل عن كثب مع الشركاء والجهات التنظيمية لتكييف وتوسيع نطاق المنصات المثبتة، مثل منصة “neurocare”، بما يتماشى مع احتياجات المملكة، ودعم الطلب المتزايد على خدمات الصحة النفسية. «

تنشط « neurocare » في منطقة الشرق الأوسط وشمال أفريقيا منذ عام 2024 من خلال شراكات استراتيجية تدعم توسيع نطاق خدمات الصحة النفسية القائمة على أفضل الممارسات، بما يُكمل حضورها السريري الراسخ في أوروبا والولايات المتحدة والمملكة المتحدة وهولندا وأستراليا. وعقب استثمار شركة «TVM Capital Healthcare»، سارعت الشركة وتيرة توسعها الإقليمي، من خلال العمل عن كثب مع الشركاء المحليين والجهات التنظيمية لتأسيس وتوسيع نطاق منصتها المتكاملة التي توفر تقنيات التعديل العصبي والتغذية الراجعة العصبية، إلى جانب خدمات الرعاية السريرية في المملكة العربية السعودية. وبالتوازي مع ذلك، تواصل « neurocare » تعزيز إتاحة تقنيات التعديل العصبي القائمة على الأدلة، من خلال دعم الجهود العالمية لتأمين مسارات التعويضات التأمينية لتقنية التحفيز المغناطيسي عبر الجمجمة (TMS) والتقنيات ذات الصلة.

في وقت تُبرز فيه الديناميكيات الإقليمية أهمية وجود أنظمة رعاية صحية مرِنة وشاملة للصحة النفسية، يمكن لمنصة « neurocare» دعم المرضى ومقدّمي الرعاية الصحية خلال فترات تزايد الحاجة، من خلال تقديم حلول رعاية موثوقة ومُخصّصة ومتاحة محليًا.

نبذة عن neurocare Group AG

طوّرت شركة « neurocare Group AG» منصة متكاملة للصحة النفسية قائمة على أفضل الممارسات، تمكّن الأطباء من تقديم أفضل مستويات الرعاية لمرضاهم عبر خطط علاجية مخصّصة، وذلك لمجموعة متنوعة من الحالات النفسية أو العصبية، مع تحقيق نتائج سريرية أكثر استدامة.
وتجمع هذه الخطط العلاجية بين أساليب وأدوات مبتكرة، مثل العلاج النفسي، وتعديل النشاط العصبي، وتحسين جودة النوم، إلى جانب العلاج الدوائي. وبعد إجراء تقييم شامل لحالة المريض، تدعم « neurocare» الأطباء في تطوير خطط علاجية مخصّصة تعزّز القدرة على التنظيم الذاتي، والمرونة النفسية، والمهارات الاجتماعية، مع الحفاظ على الكفاءة من حيث التكلفة ضمن أنظمة الرعاية الصحية.

يتم تطوير العناصر التكنولوجية الأساسية لمنصة « neurocare» داخليًا، وتشمل أجهزة متقدمة للتحفيز المغناطيسي عبر الجمجمة (TMS)   وتخطيط كهربائية الدماغ (EEG)، بالإضافة إلى منصة برمجية قائمة على الحوسبة السحابية، وأكاديمية إلكترونية تزوّد المتخصصين بالأدوات والمعرفة في علوم الأعصاب اللازمة لتطبيق هذه الأساليب بشكل صحيح في الممارسة السريرية.

تُطبَّق منصة « neurocare» حاليًا في عيادات الشركة الخاصة في كلٍّ من الولايات المتحدة والمملكة المتحدة وهولندا وأستراليا، بالإضافة إلى عدد متزايد من العيادات التابعة لجهات خارجية.

neurocaregroup.com

بيانات الاتصال:

Sally Remington (سالي ريمينغتون)
neurocare group AG
[email protected]

نبذة عن   TVM Capital Healthcare

تُعد ««TVM Capital Healthcare مستثمرًا عالميًا في مجال الملكية الخاصة ومشغّلًا يركّز على الرعاية التخصصية ورأس المال الموجّه لنمو قطاع الرعاية الصحية في الأسواق الناشئة. وبخبرة عالمية تمتد لنحو 40 عامًا في الاستثمار والتشغيل، منها 15 عامًا في الأسواق الناشئة، تعمل الشركة على بناء وتوسيع نطاق الشركات في جنوب شرق آسيا والشرق الأوسط، إلى جانب الاستثمار في شركات الابتكار في مجال الرعاية الصحية في الولايات المتحدة وأوروبا، وتوجيه توسّعها إلى هذه الأسواق.
وتُساهم الشركات التابعة لمحفظة «TVM Capital Healthcare» في تعزيز إتاحة خدمات الرعاية الصحية، وتحسين نتائج المرضى، بما يتماشى مع أجندات التحوّل الوطني لقطاع الرعاية الصحية.

tvmcapitalhealthcare.com

بيانات الاتصال:

Holly Radel (هولي رادل)
TVM Capital Healthcare

[email protected]

المرفق


GLOBENEWSWIRE (Distribution ID 1001179814)